Optiver Holding
FATE icon

Optiver Holding’s Fate Therapeutics FATE Stock Holding History

Optiver Holding’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Buy
+10
New +$19 ﹤0.01% 2696
2026
Q1 		– Sell
-1,132
Closed -$1.11K – 2457
2025
Q4 		$1.11K Sell
1,132
-1,659
-59% -$1.99K ﹤0.01% 2199
2025
Q3 		$3.52K Buy
2,791
+1,662
+147% +$1.79K ﹤0.01% 2069
2025
Q2 		$1.26K Buy
1,129
+2
+0.2% +$2 ﹤0.01% 1377
2025
Q1 		$890 Buy
1,127
+557
+98% +$683 ﹤0.01% 1288
2024
Q4 		$940 Buy
+570
New +$1.44K ﹤0.01% 987
2024
Q3 		– Sell
-858
Closed -$2.81K – 994
2024
Q2 		$2.81K Buy
+858
New +$3.76K ﹤0.01% 829

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Optiver Holding's FATE Position: Q2 2026 in Review

Optiver Holding opened a new position in Fate Therapeutics (FATE) in Q2 2026: 10 shares worth $27. The stake represents ﹤0.01% of the portfolio and ranks #2696 among its holdings. This is a return to the name: Optiver Holding previously reported a position in FATE as recently as Q4 2025.

Optiver Holding first reported a position in FATE in Q2 2024 and has held it in 7 quarters since. The position peaked at $3.52K in Q3 2025. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Optiver Holding held 10 shares of Fate Therapeutics worth $27 as of Q2 2026.
  • Fate Therapeutics was a new Optiver Holding position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2696 holding.
  • Optiver Holding first reported a position in Fate Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Optiver Holding's Fate Therapeutics position peaked at $3.52K in Q3 2025.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.